MA55947A - Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial - Google Patents

Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial

Info

Publication number
MA55947A
MA55947A MA055947A MA55947A MA55947A MA 55947 A MA55947 A MA 55947A MA 055947 A MA055947 A MA 055947A MA 55947 A MA55947 A MA 55947A MA 55947 A MA55947 A MA 55947A
Authority
MA
Morocco
Prior art keywords
lysosomial
pharmaceutical compositions
storage disorders
uses directed
directed
Prior art date
Application number
MA055947A
Other languages
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55947(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA55947A publication Critical patent/MA55947A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055947A 2016-08-11 2017-08-11 Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial MA55947A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders

Publications (1)

Publication Number Publication Date
MA55947A true MA55947A (fr) 2022-03-23

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055947A MA55947A (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial
MA43876A MA43876B1 (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43876A MA43876B1 (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale

Country Status (30)

Country Link
US (4) US11400067B2 (fr)
EP (4) EP4342461A3 (fr)
JP (4) JP7393943B2 (fr)
KR (4) KR102467953B1 (fr)
CN (3) CN121360108A (fr)
AU (3) AU2017308864B2 (fr)
CA (1) CA3033557A1 (fr)
CY (2) CY1121345T1 (fr)
DK (2) DK3359146T3 (fr)
ES (2) ES2849566T3 (fr)
FI (1) FIC20260014I1 (fr)
HK (1) HK1253282B (fr)
HR (2) HRP20190344T1 (fr)
HU (2) HUE041914T2 (fr)
IL (3) IL264610B2 (fr)
LT (3) LT3359146T (fr)
MA (2) MA55947A (fr)
MD (2) MD3482754T2 (fr)
ME (1) ME03340B (fr)
MX (2) MX384447B (fr)
NZ (3) NZ790895A (fr)
PL (2) PL3359146T3 (fr)
PT (2) PT3359146T (fr)
RS (2) RS58478B1 (fr)
RU (1) RU2749515C2 (fr)
SG (1) SG11201901048VA (fr)
SI (2) SI3359146T1 (fr)
SM (2) SMT202100050T1 (fr)
TN (1) TN2019000032A1 (fr)
WO (1) WO2018029657A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102467953B1 (ko) 2016-08-11 2022-11-16 인트라바이오 리미티드 리소좀 축적 질환과 관련된 약제 조성물 및 용도
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
BR112021010923A2 (pt) 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
KR20250171484A (ko) 2019-03-02 2025-12-08 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
US20220362189A1 (en) 2019-06-28 2022-11-17 Intrabio Ltd. Combination therapy with acetyl-leucine and miglustat
WO2022264037A1 (fr) * 2021-06-14 2022-12-22 Intrabio Ltd. Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (fr) * 2008-03-14 2009-09-17 Irm Llc Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
JP2015518872A (ja) * 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
MA43828B1 (fr) * 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
KR102467953B1 (ko) * 2016-08-11 2022-11-16 인트라바이오 리미티드 리소좀 축적 질환과 관련된 약제 조성물 및 용도

Also Published As

Publication number Publication date
DK3482754T3 (da) 2021-02-01
IL264610A (en) 2019-02-28
RU2021115932A (ru) 2021-06-08
AU2025203479A1 (en) 2025-05-29
US20220331278A1 (en) 2022-10-20
CN109843275B (zh) 2026-04-24
US12433863B2 (en) 2025-10-07
PL3359146T3 (pl) 2019-07-31
NZ790895A (en) 2026-03-27
KR20190039226A (ko) 2019-04-10
EP3482754A1 (fr) 2019-05-15
PL3482754T3 (pl) 2021-07-05
EP3482754B1 (fr) 2020-12-23
PT3359146T (pt) 2019-03-27
FIC20260014I1 (fi) 2026-04-27
ME03340B (fr) 2019-10-20
CY1121345T1 (el) 2020-05-29
MA43876A (fr) 2018-08-15
IL264610B2 (en) 2024-12-01
EP3865126A1 (fr) 2021-08-18
MD3359146T2 (ro) 2019-04-30
HRP20190344T1 (hr) 2019-04-19
MA43876B1 (fr) 2019-04-30
SI3482754T1 (sl) 2021-04-30
CN109843275A (zh) 2019-06-04
CN121360108A (zh) 2026-01-20
TN2019000032A1 (en) 2020-07-15
BR112019002719A2 (pt) 2019-05-14
KR102467953B1 (ko) 2022-11-16
KR20240110078A (ko) 2024-07-12
US12433862B2 (en) 2025-10-07
LTPA2026517I1 (fr) 2026-05-11
HK1253282B (en) 2020-02-07
RU2019106493A3 (fr) 2020-10-26
HUE041914T2 (hu) 2019-06-28
JP2019524821A (ja) 2019-09-05
SG11201901048VA (en) 2019-03-28
RU2019106493A (ru) 2020-09-11
NZ790894A (en) 2026-03-27
CN121360107A (zh) 2026-01-20
MX384447B (es) 2025-03-14
US20190201359A1 (en) 2019-07-04
JP7393943B2 (ja) 2023-12-07
MX2021008432A (es) 2021-08-19
JP2025188157A (ja) 2025-12-25
JP2024059863A (ja) 2024-05-01
NZ750391A (en) 2026-03-27
LT3482754T (lt) 2021-05-10
AU2023202903B2 (en) 2025-03-06
MX2019001577A (es) 2019-08-29
MD3482754T2 (ro) 2021-05-31
RS61442B1 (sr) 2021-03-31
HRP20210153T1 (hr) 2021-05-28
US11400067B2 (en) 2022-08-02
IL327244A (en) 2026-05-01
CA3033557A1 (fr) 2018-02-15
EP4342461A2 (fr) 2024-03-27
AU2017308864B2 (en) 2023-06-01
AU2023202903A1 (en) 2023-05-25
DK3359146T3 (en) 2019-04-08
CY1123844T1 (el) 2022-05-27
EP3359146A1 (fr) 2018-08-15
IL314107A (en) 2024-09-01
US20260027077A1 (en) 2026-01-29
PT3482754T (pt) 2021-02-03
HUE052837T2 (hu) 2021-05-28
JP2022050564A (ja) 2022-03-30
ES2849566T3 (es) 2021-08-19
SI3359146T1 (sl) 2019-05-31
JP7757446B2 (ja) 2025-10-21
HK1253282A1 (en) 2019-06-14
RS58478B1 (sr) 2019-04-30
US20240197663A1 (en) 2024-06-20
LT3359146T (lt) 2019-04-25
AU2017308864A1 (en) 2019-02-21
KR102412724B1 (ko) 2022-06-23
KR20220044372A (ko) 2022-04-07
EP3359146B1 (fr) 2019-01-23
EP4342461A3 (fr) 2024-05-29
SMT202100050T1 (it) 2021-03-15
WO2018029657A1 (fr) 2018-02-15
SMT201900154T1 (it) 2019-05-10
IL264610B1 (en) 2024-08-01
ES2716133T3 (es) 2019-06-10
RU2749515C2 (ru) 2021-06-11
KR20220154849A (ko) 2022-11-22

Similar Documents

Publication Publication Date Title
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
EP3500255A4 (fr) Compositions pharmaceutiques ophtalmiques et utilisations associées
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
EP3697792A4 (fr) Composés dihydropyrimidine et utilisations de ceux-ci en médecine
EP3426348A4 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
EP3305103A4 (fr) Unité d'atomisation
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
EP3445365A4 (fr) Inhibiteurs d'ezh2 et leurs utilisations
EP3315035A4 (fr) Unité d'atomisation
MA42196A (fr) Particules de fumarate de diméthyle et leurs compositions pharmaceutiques
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
EP3436482A4 (fr) Anticorps, compositions pharmaceutiques et procédés
MA44391A (fr) Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
EP3419599A4 (fr) Formulations d'antagonistes d'il-6 et leurs utilisations
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP3364958A4 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
MA43361A (fr) Composition pour le soin et la protection de cultures
EP3434285A4 (fr) Composition pharmaceutique et ses utilisations
EP3658554A4 (fr) Composés dihydropyrimidine et utilisations de ceux-ci en médecine
EP2956149A4 (fr) Compositions pharmaceutiques destinées au traitement d'helicobacter pylori
MA44968A (fr) Esters d'oxaborole et leurs utilisations
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
PL3482754T3 (pl) Kompozycje farmaceutyczne i zastosowania ukierunkowane na lizosomalne zaburzenia spichrzeniowe
EP3675860A4 (fr) Pyrimidines substituées, compositions pharmaceutiques et méthodes thérapeutiques associées
EP3468559A4 (fr) Méthodes d'utilisation et combinaisons pharmaceutiques d'inhibiteurs de hdac avec des inhibiteurs bet